These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Update from the 5th Conference on Retroviruses and Opportunistic Infections. Vazquez E. Posit Aware; 1998 Nov; 9(3):21-3. PubMed ID: 11365483 [Abstract] [Full Text] [Related]
4. Failure of double protease inhibitor therapy as a salvage therapy for HIV-infected patients resistant to conventional triple therapy. Rockstroh JK, Altfeld M, Kupfer B, Kaiser R, Fätkenheuer G, Salzberger B, Schneweis KE, Spengler U. Eur J Med Res; 1999 Jul 28; 4(7):271-4. PubMed ID: 10425264 [Abstract] [Full Text] [Related]
5. Antiretroviral rounds. When success is a pain. Bartlett JG, del Rio C. AIDS Clin Care; 2001 Aug 28; 13(8):74-5. PubMed ID: 11547461 [No Abstract] [Full Text] [Related]
6. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy. Reiser M, Salzberger B, Stiepel A, Hoetelmans R, Diehl V, Fätkenheuer G. Eur J Med Res; 1999 Feb 25; 4(2):54-8. PubMed ID: 10066640 [Abstract] [Full Text] [Related]
8. A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. Fischl MA, Ribaudo HJ, Collier AC, Erice A, Giuliano M, Dehlinger M, Eron JJ, Saag MS, Hammer SM, Vella S, Morse GD, Feinberg JE, Demeter LM, Eshleman SH, Adult AIDS Clinical Trials Group 388 Study Team. J Infect Dis; 2003 Sep 01; 188(5):625-34. PubMed ID: 12934177 [Abstract] [Full Text] [Related]